ADAPY

SEC source: 0001104659-24-004563 · tm243270-15_4seq1.xml · nonDerivative · entry 3

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,257

F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F9 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer

SEC source: 0001104659-24-004563 · tm243270-15_4seq1.xml · nonDerivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,785

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 3

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,015

F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F9 · balance_after: The ADSs reported in his Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,785

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004560 · tm243270-13_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,023

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer.

SEC source: 0001104659-24-004564 · tm243270-16_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer.

SEC source: 0001104659-24-004563 · tm243270-15_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,363

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,233 ADSs and RSU-style options and other options covering an aggregate of 9,170,666 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,023

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004527 · tm243270-9_4seq1.xml · derivative · entry 2

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires 2034-01-15

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

SEC source: 0001104659-24-004527 · tm243270-9_4seq1.xml · derivative · entry 1

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-004530 · tm243270-11_4seq1.xml · derivative · entry 1

Hege Kristen · CIK 0001299171 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,906

Underlying: Ordinary Shares · 81,906 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-24-004531 · tm243270-12_4seq1.xml · derivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-24-004531 · tm243270-12_4seq1.xml · derivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-004520 · tm243270-5_4seq1.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,696,272

Underlying: Ordinary Shares · 1,696,272 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 424,068 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 424,068 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-24-004520 · tm243270-5_4seq1.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,633,296

Underlying: Ordinary Shares · 7,633,296 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 1,908,324 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 159,024 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 159,132 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-004524 · tm243270-7_4seq1.xml · derivative · entry 2

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires 2034-01-15

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

SEC source: 0001104659-24-004524 · tm243270-7_4seq1.xml · derivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001209191-24-001773 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,950

Underlying: Ordinary Shares · 40,950 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-24-004528 · tm243270-10_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-24-004528 · tm243270-10_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-004525 · tm243270-8_4seq1.xml · derivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires 2034-01-15

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

SEC source: 0001104659-24-004525 · tm243270-8_4seq1.xml · derivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-004523 · tm243270-6_4seq1.xml · derivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-24-004523 · tm243270-6_4seq1.xml · derivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-003745 · tm243270-4_4seq1.xml · nonDerivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,874

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer.

SEC source: 0001104659-24-003742 · tm243270-1_4seq1.xml · nonDerivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,388

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer.

SEC source: 0001104659-24-003743 · tm243270-2_4seq1.xml · nonDerivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,841

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 46,288 ADSs and RSU-style options and other options covering an aggregate of 6,366,626 ordinary shares of the Issuer.

SEC source: 0001104659-24-003744 · tm243270-3_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,874

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer.

SEC source: 0001104659-24-003745 · tm243270-4_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer.

SEC source: 0001104659-24-003742 · tm243270-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,395

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer.

SEC source: 0001104659-24-003743 · tm243270-2_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 46,288 ADSs and RSU-style options and other options covering an aggregate of 6,366,626 ordinary shares of the Issuer.

SEC source: 0001104659-24-003744 · tm243270-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer.

SEC source: 0001104659-23-097853 · tm2325388-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,449

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 158,622 ADSs and RSU-style options and other options covering an aggregate of 27,461,190 ordinary shares of the Issuer.

SEC source: 0001104659-23-086416 · tm2320966-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,718

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 83,637 ADSs and RSU-style options and other options covering an aggregate of 7,864,224 ordinary shares of the Issuer.

SEC source: 0001104659-23-079700 · tm2320966-1_4seq1.xml · nonDerivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,056

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on July 5, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.9100 to $0.9211, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 611,224 ADSs and share options covering an aggregate of 11,093,593 ordinary shares of the Issuer. Included in the 611,224 ADSs are 200,646 ADSs held by the Garry E. Menzel Revocable Trust of 2022 (the "Menzel Trust") and 200,647 ADSs held by the Mary E. Henshall Revocable Trust of 2022 (the "Henshall Trust"). The Reporting Person is the trustee of the Menzel Trust and the Reporting Person's spouse is the trustee of the Henshall Trust and, as such, the Reporting Person may be deemed to beneficially own these securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust and the Henshall Trust.

SEC source: 0001104659-23-078201 · tm2320409-10_4seq1.xml · derivative · entry 3

Hegde Priti · CIK 0001880034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,376

Underlying: Ordinary Shares · 152,376 shares

Expires 2032-12-14

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F7 · derivative.exercise_price: The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F8 · derivative.exercise_date: Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025.

SEC source: 0001104659-23-078201 · tm2320409-10_4seq1.xml · derivative · entry 2

Hegde Priti · CIK 0001880034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,746

Underlying: Ordinary Shares · 109,746 shares

Expires 2031-12-08

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F5 · derivative.exercise_price: The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F6 · derivative.exercise_date: Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025.

SEC source: 0001104659-23-078201 · tm2320409-10_4seq1.xml · derivative · entry 1

Hegde Priti · CIK 0001880034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,464

Underlying: Ordinary Shares · 226,464 shares

Expires 2031-08-24

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F3 · derivative.exercise_price: The exercise price was converted from GBP1.39, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable as to 127,386 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 7,077 Ordinary Shares on the twenty-fifth of each month from July 25, 2023 through August 25, 2024.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 6

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,376

Underlying: Ordinary Shares · 152,376 shares

Expires 2032-12-14

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F11 · derivative.exercise_price: The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F12 · derivative.exercise_date: Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 5

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,746

Underlying: Ordinary Shares · 109,746 shares

Expires 2031-12-08

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F9 · derivative.exercise_price: The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F10 · derivative.exercise_date: Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 4

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,746

Underlying: Ordinary Shares · 109,746 shares

Expires 2030-12-09

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F7 · derivative.exercise_price: The exercise price was converted from GBP2.76, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F8 · derivative.exercise_date: Currently exercisable as to 68,586 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 2,286 Ordinary Shares on the first of each month from August 1, 2023 through December 1, 2024 and 2,298 Ordinary Shares on January 1, 2025.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 3

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,348

Underlying: Ordinary Shares · 45,348 shares

Expires 2029-12-18

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F5 · derivative.exercise_price: The exercise price was converted from GBP1.40, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F6 · derivative.exercise_date: Currently exercisable as to 39,684 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 944 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2024.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 2

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,868

Underlying: Ordinary Shares · 56,868 shares

Expires 2029-04-10

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F5 · derivative.exercise_price: The exercise price was converted from GBP1.40, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078197 · tm2320409-9_4seq1.xml · derivative · entry 1

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,212

Underlying: Ordinary Shares · 73,212 shares

Expires 2028-12-12

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of sharesof TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F3 · derivative.exercise_price: The exercise price was converted from GBP0.70, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 7

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,158,776

Underlying: Ordinary Shares · 2,158,776 shares

Expires 2032-12-14

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F9 · derivative.exercise_price: The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 6

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,715,816

Underlying: Ordinary Shares · 2,715,816 shares

Expires 2031-12-08

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F8 · derivative.exercise_price: The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 5

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,846

Underlying: Ordinary Shares · 57,846 shares

Expires 2031-12-08

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F8 · derivative.exercise_price: The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 4

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,568,026

Underlying: Ordinary Shares · 3,568,026 shares

Expires 2028-07-25

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F7 · derivative.exercise_price: The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 3

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,700

Underlying: Ordinary Shares · 359,700 shares

Expires 2028-07-25

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F7 · derivative.exercise_price: The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 2

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,251,966

Underlying: Ordinary Shares · 1,251,966 shares

Expires 2027-12-07

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.

F6 · derivative.exercise_price: The exercise price was converted from GBP0.07, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.